Jinhua Wen
Nanchang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Correction: OATP1A2 mediates Aβ1-42 transport and may be a novel target for the treatment of Alzheimer's disease.
Journal: Frontiers in pharmacology
Published: June 09, 2026
Putative Modulation of OATP1A2 and P-gp Expression at the Blood-Brain Barrier by Nrf2-PXR: An Associative Hypothesis for Amyloid-β Transport in Alzheimer's Disease.
Journal: International journal of molecular sciences
Published: May 17, 2026
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 11, 2025
OATP1A2 mediates Aβ1-42 transport and may be a novel target for the treatment of Alzheimer's disease.
Journal: Frontiers in pharmacology
Published: June 04, 2024
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems.
Journal: Current drug metabolism
Published: November 28, 2023
Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats.
Journal: Fundamental & clinical pharmacology
Published: July 30, 2022
Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer's Disease and Autism Spectrum Disorder.
Journal: CNS & neurological disorders drug targets
Published: March 05, 2022
Response to Comment on "Expression of Oatp2 in the Brain and Liver of Alzheimer Disease Mouse Model".
Journal: ACS chemical neuroscience
Published: May 20, 2021
Uptake of Aβ by OATPs might be a new pathophysiological mechanism of Alzheimer disease.
Journal: BMC neuroscience
Published: December 10, 2020
Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19.
Journal: Frontiers in pharmacology
Published: April 21, 2020
Last Updated: 09/26/2026